Barclays Increases Kenvue (NYSE:KVUE) Price Target to $23.00

Kenvue (NYSE:KVUE) had its target price hoisted by stock analysts at Barclays from $21.00 to $23.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm presently has an “equal weight” rating on the stock. Barclays‘s price objective would indicate a potential downside of 2.21% from the company’s current price.

KVUE has been the topic of a number of other reports. UBS Group dropped their target price on shares of Kenvue from $23.00 to $21.00 and set a “neutral” rating on the stock in a research report on Friday, February 7th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $24.00 price objective on shares of Kenvue in a report on Monday, February 3rd. Piper Sandler boosted their target price on Kenvue from $24.00 to $27.00 and gave the company an “overweight” rating in a report on Monday, February 24th. Deutsche Bank Aktiengesellschaft cut Kenvue from a “buy” rating to a “hold” rating and decreased their target price for the company from $25.00 to $24.00 in a research report on Thursday, December 12th. Finally, Canaccord Genuity Group lifted their price target on Kenvue from $24.00 to $29.00 and gave the stock a “buy” rating in a research report on Wednesday, March 5th. One analyst has rated the stock with a sell rating, eight have given a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $24.00.

Kenvue Stock Up 0.5 %

Shares of NYSE KVUE opened at $23.52 on Thursday. The business has a 50-day moving average of $22.22 and a two-hundred day moving average of $22.45. The company has a market capitalization of $44.95 billion, a price-to-earnings ratio of 44.40, a price-to-earnings-growth ratio of 2.62 and a beta of 1.25. Kenvue has a 1 year low of $17.67 and a 1 year high of $24.46. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69.

Kenvue (NYSE:KVUE) last posted its earnings results on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, hitting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. On average, analysts forecast that Kenvue will post 1.14 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of KVUE. Wealth Enhancement Advisory Services LLC grew its holdings in Kenvue by 14.3% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 603,648 shares of the company’s stock valued at $12,888,000 after buying an additional 75,332 shares during the last quarter. Lansforsakringar Fondforvaltning AB publ acquired a new position in Kenvue in the 4th quarter valued at $13,101,000. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in Kenvue in the 4th quarter worth about $26,982,000. Brooklyn FI LLC purchased a new stake in Kenvue in the fourth quarter valued at approximately $948,000. Finally, Azzad Asset Management Inc. ADV raised its stake in Kenvue by 3.0% during the fourth quarter. Azzad Asset Management Inc. ADV now owns 291,915 shares of the company’s stock worth $6,232,000 after purchasing an additional 8,532 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.